Recruiting

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

ClinicalTrials.gov IDNCT07495852

PhasePHASE3

Enrollment510

SponsorGlaukos Corporation

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Glaucoma

About this study

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Interventions

Drug: Gen 2 Travoprost Intracameral Implant — Travoprost
Drug: Timolol eye drops 0.5% — Timolol 0.5%
Procedure: Sham Procedure — Sham implant administration
Other: placebo eye drops — Artificial Tears

Primary outcomes

Intraocular pressure (IOP) (3 months)

Eligibility information

Inclusion Criteria: * Diagnosis of Ocular Hypertension or Open-Angle Glaucoma in the study eye Exclusion Criteria: * Prior incisional glaucoma surgery in the study eye * Prior argon laser trabeculoplasty (ALT) in the study eye * Prior minimally invasive glaucoma (MIGS) surgery in the study eye

Study locations

Glaukos Investigative Site, Dothan, Alabama 36301 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-30.